Page 2 - Carnot
P. 2
The consortium Target markets
for leukemia Drugs
Biotechnologies
and related In vitro diagnostic
Healthtech
diseases
partnering
research
OPALE offers its partners a unique continuum
in the leukemia field: an unparalleled array of
competencies, from scientific innovation to industrial
and medical valorization.
Through its 27 entities spread over the French
territory, OPALE is a national consortium gathering
most of France’s academic research and
development strengths in the leukemia and related
diseases field: every year, they produce more than
350 papers in top-tier peer-reviewed medical
journals and there is a portfolio of close to 59
active patents.
